← Back to Search

Monoclonal Antibodies

First in Human Study of M6223

Nashville, TN
Phase 1
Waitlist Available
Research Sponsored by EMD Serono Research & Development Institute, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new cancer drug to see if it is safe and effective.

See full description

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Part1B: M6223 + Bintrafusp alfaExperimental Treatment2 Interventions
Group II: Part 1A: M6223 MonotherapyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bintrafusp alfa
Not yet FDA approved
M6223
2020
Completed Phase 1
~60

Find a Location

Closest Location:Sarah Cannon Research Institute· Nashville, TN

Who is running the clinical trial?

EMD Serono Research & Development Institute, Inc.Lead Sponsor
85 Previous Clinical Trials
22,676 Total Patients Enrolled
Merck KGaA, Darmstadt, GermanyIndustry Sponsor
448 Previous Clinical Trials
122,242 Total Patients Enrolled
Medical ResponsibleStudy DirectorMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
301 Previous Clinical Trials
61,212 Total Patients Enrolled

Media Library

Bintrafusp alfa (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04457778 — Phase 1
Metastatic Tumor Research Study Groups: Part 1A: M6223 Monotherapy, Part1B: M6223 + Bintrafusp alfa
Metastatic Tumor Clinical Trial 2023: Bintrafusp alfa Highlights & Side Effects. Trial Name: NCT04457778 — Phase 1
Bintrafusp alfa (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04457778 — Phase 1
~10 spots leftby Mar 2026